Table 2.

Demographic and clinical characteristics of the study population with AF at baseline according to major bleeding event

Variables	Without bleeding (n = 244)	With Bleeding (n = 24)	P value
Age (y)	7 3.7 ± 10.0	71.9 ± 12.0	0.42
Gender male n (%)	94 (39)	10 (42)	0.83
DM n (%)	169 (70)	16 (67)	0.82
Dialysis vintage (years)	0.0 (0.0–3.0)	0.0 (0.0–3.8)	0.83
Kt/V	1.36 ± 0.17	1.26 ± 0.25	0.006
Vascular access			0.46
Arterio-venous fistula n (%)	89 (37)	11 (46)
Arterio-venous graft n (%)	17 (7)	4 (17)
Central venous catheter n (%)	136 (56)	9 (37)
Heparin dose during HD session (units)	2500 (0–2500)	1250 (0–2500)	0.33
Comorbidity index	8.7 ± 3.2	9.0 ± 3.1	0.63
Functional status (need in nursing care) n (%)	142 (59)	9 (37)	0.03
Dementia n (%)	43 (18)	4 (17)	0.90
A-V access thrombosis n (%)	50 (21)	7 (29)	0.43
Left atrium size (cm)	4.3 ± 0.6	4.4 ± 0.5	0.54
Time since AF diagnosis (years)	4.0 (1.0–7.0)	2.0 (0.0–6.0)	0.26
All-cause death n (%)	193 (80)	21 (88)	0.59
Warfarin use n (%)	82 (34)	9 (37)	0.82
Aspirin use n (%)	137 (57)	16 (67)	0.39
Clopidogrel use n (%)	54 (22)	7 (29)	0.45
Dual antiplatelet therapy n (%)	34 (14)	7 (29)	0.07
Enoxaparin use n (%)	31 (13)	3 (12)	0.69
PPI n (%)	130 (54)	17 (71)	0.13
INR	1.2 (1.1–1.4)	1.3 (1.1–1.7)	0.41
Hb (g/dL)	10.1 ± 1.7	9.5 ± 1.7	0.40
Platelets(×103/mm3)	196.8 ± 73.4	184.9 ± 63.6	0.47
Mean HAS-BLED score	4.5 ± 1.2	4.4 ± 1.1	0.54
HAS-BLED score			0.92
0 n (%)	0 (0)	0 (0)
1 n (%)	2 (0.8)	0 (0)
2 n (%)	3 (1.2)	1 (4.2)
3 n (%)	41 (16.5)	4 (16.7)
4 n (%)	76 (31.0)	8 (33.3)
5 n (%)	76 (31.0)	7 (29.4)
6 n (%)	36 (15.4)	4 (16.7)
7 n (%)	9 (3.7)	0 (0)
8 n (%)	1 (0.4)	0 (0)
9 n (%)	0 (0)	0 (0)

Continuous variables with normal distribution are expressed as means (SDs), as medians (interquartile ranges) for non–normally distributed data, and categorical variables are expressed as percentages

Abbreviations: AF atrial fibrillation, HD hemodialysis, DM diabetes mellitus, GI gastrointestinal, PPI proton pump inhibitor, Hb hemoglobin